---
title: "RET fusion-targeted therapies market to grow significantly by 2034 with the approval of selpercatinib and pralsetinib for RET fusion-positive tumors."
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/273756406.md"
description: "The market for RET fusion-targeted therapy is poised for significant growth, propelled by increasing recognition of the cancer-causing potential of RET gene fusions and positive results from clinical trials. Approval of targeted drugs like selpercatinib and pralsetinib for RET fusion-positive tumors has further fueled this expansion. The market size is expected to see a notable increase in sales, reaching an estimated value of $X billion in the coming years."
datetime: "2026-01-26T22:34:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273756406.md)
  - [en](https://longbridge.com/en/news/273756406.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273756406.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/273756406.md) | [English](https://longbridge.com/en/news/273756406.md)


# RET fusion-targeted therapies market to grow significantly by 2034 with the approval of selpercatinib and pralsetinib for RET fusion-positive tumors.

The market for RET fusion-targeted therapy is poised for significant growth, propelled by increasing recognition of the cancer-causing potential of RET gene fusions and positive results from clinical trials. Approval of targeted drugs like selpercatinib and pralsetinib for RET fusion-positive tumors has further fueled this expansion. The market size is expected to see a notable increase in sales, reaching an estimated value of $X billion in the coming years.

### 相關股票

- [Roche (RHHBY.US)](https://longbridge.com/zh-HK/quote/RHHBY.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [Eli Lilly (LLY.US)](https://longbridge.com/zh-HK/quote/LLY.US.md)
- [Blueprint Med (BPMC.US)](https://longbridge.com/zh-HK/quote/BPMC.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md)

## 相關資訊與研究

- [Corvus’ Soquelitinib Trial Completion Adds a New Catalyst in the Atopic Dermatitis Market](https://longbridge.com/zh-HK/news/278917368.md)
- [Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data](https://longbridge.com/zh-HK/news/278565911.md)
- [BUZZ-MiNK Therapeutics rises as it wins funding for child cancer cell therapy](https://longbridge.com/zh-HK/news/278530484.md)
- [MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers | INKT Stock News](https://longbridge.com/zh-HK/news/278526337.md)
- [C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric Oncology | INKT Stock News](https://longbridge.com/zh-HK/news/278521475.md)